Isomorphic Labs announces collaboration with Lilly
Isomorphic Labs →Isomorphic Labs announced a strategic research collaboration with Eli Lilly and Company to discover small-molecule therapeutics against multiple targets. The announcement described an upfront cash payment of [figure hidden] and eligibility for up to [figure hidden] in performance-based milestone payments, excluding the upfront payment and potential tiered royalties on net sales. These are contractual terms and contingent opportunities, not recognized revenue or guaranteed receipts. The release identified the collaboration as Isomorphic Labs’ first pharmaceutical partnership. It described combining the company’s predictive and generative AI models with Lilly’s development programs, building on work with Google DeepMind on an expanded generation of AlphaFold.